Literature DB >> 3861194

Suppression of clonal evolution in two chronic myelogenous leukaemia patients treated with leucocyte interferon.

M Talpaz, J M Trujillo, W N Hittelman, M J Keating, J U Gutterman.   

Abstract

Two patients with Philadelphia chromosome-positive (Ph1+) chronic myelogenous leukaemia (CML) were treated with human leucocyte interferon (HuIFN-alpha). Karyotypic changes in addition to the Ph1 chromosome developed in these patients before the start of HuIFN-alpha treatment. In one patient the administration of HuIFN-alpha resulted in clinical haematological remission and stable suppression of the secondary Ph1 clone. The second patient was in myeloid blastic crisis when given HuIFN-alpha. While she was receiving HuIFN-alpha, suppression of the blast cell population in the bone marrow occurred. The subsequent cytogenetic changes included a near-complete suppression of a secondary Ph 1 clone of cells carrying a deletion in the short arm of chromosome 7 and partial population of the bone marrow with primary Ph1 clone. These observations suggest a potential role for interferons in altering the progressive course of CML.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3861194     DOI: 10.1111/j.1365-2141.1985.tb07464.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Interferon alfa-2b in the treatment of chronic granulocytic leukemia.

Authors:  D E Bergsagel; R H Haas; H A Messner
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

2.  Restoration of nonclonal hematopoiesis in chronic myelogenous leukemia with interferon alpha.

Authors:  G Egert; L Kanz; G W Löhr; A A Fauser
Journal:  Blut       Date:  1990-05

3.  Prognostic factors in juvenile chronic granulocytic leukaemia.

Authors:  G Owen; I J Lewis; M Morgan; A Robinson; R F Stevens
Journal:  Br J Cancer Suppl       Date:  1992-08

4.  [Detection of nephrotoxicity of human alpha 2b interferon with special reference to the analysis of urine enzymes in patients with chronic myeloid leukemia].

Authors:  E Kurschel; U Metz-Kurschel; W Hofmann; N Niederle
Journal:  Klin Wochenschr       Date:  1987-07-15

5.  In vivo induction of HLA molecules in patients with myeloproliferative syndrome during IFN alpha treatment.

Authors:  C A Müller; J Walz; R Zinser; H J Bühring; B Steinke; H Schmidt
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.